Skip to main content

Table 3 Displays the change in the assessed imaging features between the first and second PET/MRI examination, for both chemotherapy responders and non-responders. Absolute values from the baseline as well as the follow-up PET/MRI can be found in the supplementary material (A. 2)

From: [18F]FDG PET/MRI enables early chemotherapy response prediction in pancreatic ductal adenocarcinoma

  Responder
(Mean ± SD)
Non-responder
(Mean ± SD
p-value
∆MTV50% −0.28 ± 0.18  + 1.26 ± 0.98  < 0.0001
∆ADCmean  + 0.27 ± 0.10  + 0.07 ± 0.09 0.0011
∆TLG50% −0.39 ± 0.14  + 0.63 ± 1.12 0.0054
∆SUVmax −0.24 ± 0.17 −0.33 ± 0.18 0.3372
∆SUVpeak −0.15 ± 0.13 −1.23 ± 0.25 0.8296
∆MTV2,5 −0.53 ± 0.24  + 0.05 ± 0.98 0.0696
∆TLG2,5 −0.53 ± 0.26 −0.02 ± 1.1 0.1419
∆ADCmin  + 0.33 ± 0.26 −0.07 ± 0.21 0.0080
∆ADCmax 0.24 ± 0.16 0.26 ± 0.14 0.7955